全膝关节置换术中氨甲环酸的最佳给药途径是什么?一项随机对照试验
376例接受全膝关节置换术的患者随机分为静脉单独、关节腔单独、低剂量联合(静脉+关节腔注射1g)和高剂量联合(静脉+关节腔注射2g)四组。高剂量联合组、低剂量联合组和关节腔单独组的总失血量均低于静脉单独组,但其他三组间无差异;所有组均无患者接受异体输血。结论认为关节腔给予氨甲环酸较静脉单独使用进一步减少失血,联合静脉给药未显示额外减少失血的效果。
要点
- 高剂量联合组、低剂量联合组和关节腔单独组的总失血量均低于静脉单独组。
- 所有研究组均无患者接受异体输血,组间伤口并发症无差异。
- 关节腔给予氨甲环酸较静脉单独使用进一步减少失血,联合静脉给药无额外减少失血效果。
核心结论
- 关节腔给予氨甲环酸较静脉单独使用进一步减少全膝关节置换术后的失血。
- 联合静脉给予氨甲环酸未发现进一步减少失血的额外效果。
- 需要样本量足够的研究来确认该给药途径作为全膝关节置换术首选途径的安全性。
研究设计与样本
- 2014年3月至2015年3月期间接受全膝关节置换术的376例患者随机分为四组:静脉单独组、关节腔单独组、低剂量联合组(静脉+关节腔注射1g)和高剂量联合组(静脉+关节腔注射2g)。
- 比较各组计算的总失血量、异体输血率、血红蛋白下降、症状性深静脉血栓和肺栓塞发生率、伤口并发症及假体周围关节感染。
- 总失血量采用估计全身血容量和血红蛋白丢失计算,输血决策基于预设标准。
主要发现
- 高剂量联合组总失血量为564 ± 242 mL,低剂量联合组为642 ± 242 mL,关节腔单独组为633 ± 205 mL,均低于静脉单独组的764 ± 217 mL(平均差值分别为199 mL [95% CI, 116-283 mL], p < 0.001;121 mL [95% CI, 38-205 mL], p = 0.001;131 mL [95% CI, 47-214 mL], p < 0.001)。
- 其他三组之间未发现差异。
- 所有研究组均无患者接受异体输血。
- 静脉单独组有1例患者发生症状性肺栓塞,其他组未发生其他症状性静脉血栓栓塞事件。
- 伤口并发症方面,浅表伤口坏死在静脉单独组和高剂量联合组各1例;渗液在静脉单独组、关节腔单独组、低剂量联合组和高剂量联合组分别为3%、4%、4%和7%(p = 0.572),组间无差异;无患者发生假体周围关节感染。
关键数值与推荐
- 高剂量联合组总失血量564 ± 242 mL,低剂量联合组642 ± 242 mL,关节腔单独组633 ± 205 mL,静脉单独组764 ± 217 mL。
- 高剂量联合组与静脉单独组平均差值199 mL(95% CI, 116-283 mL),p < 0.001。
- 低剂量联合组与静脉单独组平均差值121 mL(95% CI, 38-205 mL),p = 0.001。
- 关节腔单独组与静脉单独组平均差值131 mL(95% CI, 47-214 mL),p < 0.001。
- 渗液发生率:静脉单独组3%,关节腔单独组4%,低剂量联合组4%,高剂量联合组7%(p = 0.572)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要样本量足够的研究来确认该给药途径作为全膝关节置换术首选途径的安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: TKA commonly involves substantial blood loss and tranexamic acid has been used to reduce blood loss after TKA. Numerous clinical trials have documented the efficacy and safety of intravenous (IV) or intraarticular (IA) use of tranexamic acid. Combined administration of tranexamic acid also has been suggested; however, there is no consensus regarding the ideal route of tranexamic acid administration. QUESTIONS/PURPOSES: (1) To compare the efficacy of tranexamic acid in terms of total blood loss and the allogeneic transfusion rate among three routes of administration: IV alone, IA alone, and combined IV and IA. (2) To compare these regimens in terms of venous thromboembolism (VTE) and the frequency of wound complications. METHODS: In total, 376 patients undergoing TKA between March 2014 and March 2015 were randomized to four groups by the route of tranexamic acid administration: IV only, IA only, low-dose combined (IV + IA injection of 1 g), and high-dose combined (IV + IA injection of 2 g). The calculated total blood loss, allogeneic transfusion rate, decrease in hemoglobin, the frequency of symptomatic deep vein thrombosis and pulmonary embolism, wound complications, and periprosthetic joint infection were compared among the groups. Total blood loss was calculated using estimated total body blood volume and hemoglobin loss. The decision regarding when to transfuse was determined based on preset criteria. RESULTS: The high- and low-dose combined groups and the IA-only group had lower total blood loss (564 ± 242 mL, 642 ± 242 mL, and 633 ± 205 mL, respectively) than the IV-only group (764 ± 217 mL; mean differences = 199 mL [95% CI, 116-283 mL], p < 0.001; 121 mL [95% CI, 38-205 mL], p = 0.001; 131 mL [95% CI, 47-214 mL], p < 0.001); no differences were found among the other three groups. No patients in any study group received an allogeneic transfusion. One patient in the IV-only group had a symptomatic pulmonary embolism develop, but no other symptomatic VTE events occurred in any group. In addition, no differences were observed in wound complications, such as superficial wound necrosis (one patient in the IV-only and the high-dose combined group, respectively) and oozing (IV-only, IA-only, low-dose combined, high-dose combined = 3%, 4%, 4%, and 7%; p = 0.572) between the groups. No patients had a periprosthetic joint infection. CONCLUSION: IA tranexamic acid administration further reduces blood loss after TKA in comparison to IV use alone; no additional effect in further reducing blood loss was found in combination with IV tranexamic acid. Appropriately powered studies are needed to confirm the safety of this route of administration as the preferred route of administration in TKA. LEVEL OF EVIDENCE: Level I, therapeutic study.
引用
- Lee SY, Chong S, Balasubramanian D, et al. What is the Ideal Route of Administration of Tranexamic Acid in TKA? A Randomized Controlled Trial. Clin Orthop Relat Res. 2017. PMID: 28283902. doi:10.1007/s11999-017-5311-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。